Post by Parkinson's Insights

A team of scientists from Cleveland, Ohio, and Seoul National University has discovered that an immune system enzyme called 15-PGDH becomes overly active in Parkinson's, destroying protective molecules and causing severe cell-killing inflammation. By testing an oral drug that blocks this enzyme across three different models, the researchers successfully lowered toxic inflammation, kept vital brain cells alive, and restored motor control. Crucially, this treatment protects the brain without needing to clear out alpha-synuclein proteins, meaning it shields neurons even when these characteristic clumps are present. Because a matching drug targeting this exact enzyme has already safely completed Phase 1 human trials for muscle health, researchers have a head start that could significantly accelerate the timeline for bringing this potential treatment to Parkinson's clinical trials. 🚀 Scientists discover that blocking the 15-PGDH enzyme stops the destructive cycle of inflammation and oxidative stress that kills dopamine-producing cells. 🔬 The oral treatment successfully crosses the blood-brain barrier to shield neurons and significantly improve motor function in multiple models. 🛡️ Neurons are protected by disarming the brain's toxic damage response directly, meaning the therapy works even while alpha-synuclein protein clumps remain present. ⏩ Because a similar drug has already safely passed Phase 1 human clinical trials for another condition, researchers have an accelerated path toward future Parkinson's trials. 👉 Read the full story now on Parkinson's Insights https://lnkd.in/eEMhgd3q Powered by @pdbuddyapp and @nosilverbullet4pd #Parkinsons #parkinsonsresearch #parkinsonsdisease #parkinsonsawareness #Neuroscience